Associated tags: Retina, Glaucoma, Glaucoma surgery, MIGS, Health, Pharmaceutical, Optical, GKOS, Corporation, Pharmaceutical industry, NYSE, Medical Devices, Biotechnology, Conference, Patient, Surgery
Locations: ILLINOIS, CHICAGO, IL, MASSACHUSETTS, BOSTON, MA, NEW YORK CITY, UNITED STATES, NORTH AMERICA, CALIFORNIA, SG
Biotechnology,
Health,
General Health,
Pharmaceutical,
Optical,
Health Technology,
Other Science,
Medical Devices,
Research,
Surgery,
Science,
GAAP,
Investment,
Corporation,
Conference,
Webcast,
GKOS,
Patient,
IPR,
EPS,
Standard of care,
Glaucoma,
Retina Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2024.
Key Points:
- Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2024.
- “Our record first quarter results reflect successful global execution of our key strategic plans,” said Thomas Burns, Glaukos chairman and chief executive officer.
- Loss from operations in the first quarter of 2024 was $39.1 million, compared to operating loss of $33.0 million in the first quarter of 2023.
- Non-GAAP loss from operations in the first quarter of 2024 was $32.8 million, compared to non-GAAP operating loss of $26.8 million in the first quarter of 2023.
Professional Services,
Pharmaceutical,
Philanthropy,
Optical,
Sustainability,
Medical Devices,
Environment,
DEI (Diversity, Equity and Inclusion),
Surgery,
Other Philanthropy,
Environmental, Social and Governance (ESG),
Health,
DEI,
FDA,
Corporation,
Woman,
Certification,
ISO,
GKOS,
Patient,
ESG,
Idose,
GHG,
Workforce,
Glaucoma,
Retina Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2023 Sustainability Report.
Key Points:
- Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2023 Sustainability Report.
- The report highlights the company’s continued commitment and progress on its key corporate sustainability initiatives.
- The Sustainability Report can be found on the company’s website here .
- For additional information and highlights, please see Glaukos’ 2023 Sustainability Report, which can be found on the company’s website here .
Retrieved on:
Wednesday, April 10, 2024
Medical Devices,
Health,
Health Technology,
Pharmaceutical,
Optical,
Biotechnology,
GKOS,
International,
Glaucoma,
Corporation,
Conference,
Retina Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2024 financial results after the market close on Wednesday, May 1, 2024.
Key Points:
- Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2024 financial results after the market close on Wednesday, May 1, 2024.
- The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m.
- A link to the live webcast will be available on the company’s website at http://investors.glaukos.com .
- To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (International) and enter Conference ID 7935742.
Medical Devices,
Surgery,
Health Technology,
Health Insurance,
Biotechnology,
Managed Care,
General Health,
Pharmaceutical,
Health,
Optical,
Retina,
IOP,
HCPCS,
Glaucoma,
Ocular hypertension,
OAG,
OHT,
Patient,
Corporation,
APC,
Eye,
Surgeon,
CPT,
Travoprost,
GKOS,
OPPS,
Idose,
Medicare,
CMS,
Government,
Intraocular pressure The new J-code for iDose TR, J7355, is set to become effective July 1, 2024.
Key Points:
- The new J-code for iDose TR, J7355, is set to become effective July 1, 2024.
- It is expected to increase patient access in the U.S. and has been published here on the CMS website.
- “The receipt of a product-specific J-code for iDose TR supports our market access initiatives to enable broad access and coverage for patients suffering from open-angle glaucoma or ocular hypertension,” said Thomas Burns, Glaukos chairman and chief executive officer.
- iDose TR is intended to improve the standard of care by addressing the ubiquitous patient non-compliance issues and chronic side effects associated with topical glaucoma medications.
Research,
Surgery,
Medical Devices,
Health Technology,
Health,
Pharmaceutical,
General Health,
Optical,
Science,
Retina,
Glaucoma,
Refractive surgery,
ASCRS,
Corporation,
Faculty,
Cataract,
Society,
GKOS,
Convention center,
Physician Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it will present multiple scientific abstracts at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held April 5-8, 2024 in Boston, MA.
Key Points:
- Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it will present multiple scientific abstracts at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held April 5-8, 2024 in Boston, MA.
- Glaukos will be exhibiting onsite at booth #631.
- The faculty includes Ike Ahmed, MD (Moderator); Sahar Bedrood, MD; John Berdahl, MD; Manjool Shah, MD; and Blake Williamson, MD.
- The ASCRS Annual Meeting is among the largest gatherings of anterior segment physicians, medical personnel and industry executives in the ophthalmic industry.
Wearables,
Mobile Technology,
Other Health,
Seniors,
Other Science,
Pharmaceutical,
Other Technology,
Research,
Optical,
Software,
Medical Devices,
Hardware,
Consumer,
Science,
Technology,
Clinical Trials,
General Health,
Health,
Health Technology,
Diagnosis,
Newton Aycliffe,
Patient,
ARVO,
Digital health,
Quality of life,
Multimedia,
Medicare,
Clinical trial,
Medical imaging This milestone publication confirms RadiusXR's unwavering commitment to advancing ocular health and heralds a new era in visual field testing.
Key Points:
- This milestone publication confirms RadiusXR's unwavering commitment to advancing ocular health and heralds a new era in visual field testing.
- Moreover, unlike other virtual reality perimeters (VRPs), RadiusXR measures vision within the photopic range, aligning with existing visual field platforms' standards.
- "The publication of the NOVA Clinical Trial in TVST reaffirms RadiusXR's position as the leader in visual field testing innovation," remarked Ammad Khan, RadiusXR's Chief Executive Officer.
- RadiusXR's innovative approach to visual field testing represents a significant advancement in the field of ophthalmology.
Retrieved on:
Wednesday, February 21, 2024
Medical Devices,
Health,
Health Technology,
Pharmaceutical,
Optical,
Biotechnology,
Investment,
Standard of care,
Conference,
IPR,
GAAP,
Webcast,
Patent,
Patient,
FY,
Retina,
EPS,
Corporation,
GKOS,
Glaucoma Gross margin for the fourth quarter of 2023 was approximately 77%, compared to approximately 76% in the same period in 2022.
Key Points:
- Gross margin for the fourth quarter of 2023 was approximately 77%, compared to approximately 76% in the same period in 2022.
- Non-GAAP SG&A expenses for the fourth quarter of 2023 increased 22% to $62.3 million, compared to $51.1 million in the same period in 2022.
- Loss from operations in the fourth quarter of 2023 was $38.6 million, compared to operating loss of $33.7 million in the fourth quarter of 2022.
- Non-GAAP loss from operations in the fourth quarter of 2023 was $32.4 million, compared to non-GAAP operating loss of $27.4 million in the fourth quarter of 2022.
Retrieved on:
Wednesday, January 31, 2024
Medical Devices,
Health,
Surgery,
General Health,
Pharmaceutical,
Optical,
Glaucoma,
GKOS,
Corporation,
Retina,
Conference,
International Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2023 financial results after the market close on Wednesday, February 21, 2024.
Key Points:
- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2023 financial results after the market close on Wednesday, February 21, 2024.
- The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m.
- A link to the live webcast will be available on the company’s website at http://investors.glaukos.com .
- To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (International) and enter Conference ID 7935742.
Medical Devices,
Health,
Surgery,
Pharmaceutical,
Optical,
Biotechnology,
Corporation,
Retina,
GKOS,
Glaucoma,
Pharmaceutical industry Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced its preliminary, unaudited net sales for the fourth quarter and full year ended December 31, 2023.
Key Points:
- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced its preliminary, unaudited net sales for the fourth quarter and full year ended December 31, 2023.
- Preliminary and unaudited total net sales for the fourth quarter and full year of 2023 are expected to be in excess of $81 million and $313 million, respectively.
- In addition, the company reaffirms its 2024 net sales guidance range of $350 million to $360 million.
Retrieved on:
Wednesday, December 20, 2023
Health,
Medical Devices,
Surgery,
Health Technology,
Pharmaceutical,
Optical,
Biotechnology,
Retina,
Conference,
GKOS,
Glaucoma,
Corporation Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 5:15 p.m. PT in San Francisco, CA.
Key Points:
- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 5:15 p.m. PT in San Francisco, CA.
- A live and archived webcast for these events, where applicable, will be available in the Investors section of the Glaukos website at http://investors.glaukos.com .